Gibeom Nam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gibeom Nam has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Sang Jeon Chung
Department of Biopharmaceutical Convergence, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
4 shared publications - Dohee Ahn
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
3 shared publications - Xiaodi Zhao
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea
3 shared publications - Jen-Tsan Chi
Duke University
2 shared publications Jianli Wu
Department of Molecular Genetics and Microbiology
2 shared publications- Jihee Kwon
Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea
2 shared publications
Latest Publications
- 11 June 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (7) , 1678-1689
Stability-Based Proteomic Methods Add Value to Activity-Based Protein Profiling Studies
Covalent inhibitors offer powerful therapeutic advantages over noncovalent inhibitors, but like noncovalent inhibitors, they require comprehensive profiling to define their on- and off-target activities. Here, we report on the use of two stability-based proteomic methods, stability of proteins from rates of oxidation (SPROX) and thermal protein profiling (TPP), to identify protein targets of covalent inhibitors using the KRASG12C inhibitor, ARS-1620, and the proteins in H358 cell lysates as a model system. Both methods identified ligand-induced protein folding stability shifts, collectively recovering the known on-target KRAS as well as multiple off-targets. Comparative analyses of the SPROX and TPP results with previously published pull-down data sets highlighted aldehyde dehydrogenase 1A3 (ALDH1A3) as a reproducible off-target that was missed in prior work using activity-based profiling methods. MS-based covalent site mapping identified C314 as the major ARS-1620 modification site on ALDH1A3, and enzymatic assays confirmed dose-dependent inhibition. Covalent docking supported a favorable binding pose within the retinal-binding pocket. Functionally, ALDH1A3 knockdown reduced ARS-1620-mediated cell killing, supporting the role of ALDH1A3 in ARS-1620's mode-of-action. Together, these findings not only demonstrate that stability-based proteomics provides a valuable and effective strategy for covalent drug target identification but also expand our knowledge of ARS-1620's biological activity.
- 11 June 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (7) , 1678-1689
Stability-Based Proteomic Methods Add Value to Activity-Based Protein Profiling Studies
Covalent inhibitors offer powerful therapeutic advantages over noncovalent inhibitors, but like noncovalent inhibitors, they require comprehensive profiling to define their on- and off-target activities. Here, we report on the use of two stability-based proteomic methods, stability of proteins from rates of oxidation (SPROX) and thermal protein profiling (TPP), to identify protein targets of covalent inhibitors using the KRASG12C inhibitor, ARS-1620, and the proteins in H358 cell lysates as a model system. Both methods identified ligand-induced protein folding stability shifts, collectively recovering the known on-target KRAS as well as multiple off-targets. Comparative analyses of the SPROX and TPP results with previously published pull-down data sets highlighted aldehyde dehydrogenase 1A3 (ALDH1A3) as a reproducible off-target that was missed in prior work using activity-based profiling methods. MS-based covalent site mapping identified C314 as the major ARS-1620 modification site on ALDH1A3, and enzymatic assays confirmed dose-dependent inhibition. Covalent docking supported a favorable binding pose within the retinal-binding pocket. Functionally, ALDH1A3 knockdown reduced ARS-1620-mediated cell killing, supporting the role of ALDH1A3 in ARS-1620's mode-of-action. Together, these findings not only demonstrate that stability-based proteomics provides a valuable and effective strategy for covalent drug target identification but also expand our knowledge of ARS-1620's biological activity.
- Open Access
Identification of 4,5,6,7-Tetrabromo-1 H -benzotriazole (TBB) as a Small Molecule MESH1 Inhibitor that Suppresses Ferroptosis
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and contributes to diverse pathologies including ischemia-reperfusion injury and neurodegenerative disorders. Current ferroptosis inhibitors largely function as nonspecific radical-trapping antioxidants, limiting their clinical utility. We previously identified MESH1 as a key regulator of ferroptosis through its NADPH phosphatase activity. Here, we identify 4,5,6,7-tetrabromo-1 H -benzotriazole (TBB) as a small molecule inhibitor of MESH1 with an IC 50 value of 4.7 ± 0.3 µM. X-ray crystallography revealed the molecular determinants of TBB recognition which are corroborated through structure-activity relationships of TBB analogs. TBB protected multiple cell lines against ferroptosis in vitro , and this effect was mitigated by MESH1 knockdown, consistent with on-target activity. Furthermore, TBB reduced neuronal death in an ex vivo brain slice model of Alzheimer’s disease. Collectively, these findings establish TBB as a bona fide small-molecule MESH1 inhibitor that suppresses ferroptosis and establishes MESH1 as a promising therapeutic target. Graphical Depicting mechanism of TBB suppressing ferroptosis through the inhibition of MESH1. Figure Created with Biorender.com
Open AccessIdentification of 4,5,6,7-Tetrabromo-1 H -benzotriazole (TBB) as a Small Molecule MESH1 Inhibitor that Suppresses Ferroptosis
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and contributes to diverse pathologies including ischemia-reperfusion injury and neurodegenerative disorders. Current ferroptosis inhibitors largely function as nonspecific radical-trapping antioxidants, limiting their clinical utility. We previously identified MESH1 as a key regulator of ferroptosis through its NADPH phosphatase activity. Here, we identify 4,5,6,7-tetrabromo-1 H -benzotriazole (TBB) as a small molecule inhibitor of MESH1 with an IC 50 value of 4.7 ± 0.3 µM. X-ray crystallography revealed the molecular determinants of TBB recognition which are corroborated through structure-activity relationships of TBB analogs. TBB protected multiple cell lines against ferroptosis in vitro , and this effect was mitigated by MESH1 knockdown, consistent with on-target activity. Furthermore, TBB reduced neuronal death in an ex vivo brain slice model of Alzheimer’s disease. Collectively, these findings establish TBB as a bona fide small-molecule MESH1 inhibitor that suppresses ferroptosis and establishes MESH1 as a promising therapeutic target. Graphical Depicting mechanism of TBB suppressing ferroptosis through the inhibition of MESH1. Figure Created with Biorender.com
- 5 November 2024
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 113, 108263
HiMolformer: Integrating graph and sequence representations for predicting liver microsome stability with SMILES
- 5 November 2024
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 113, 108263
HiMolformer: Integrating graph and sequence representations for predicting liver microsome stability with SMILES
- Open Access
Exploring the Anti-Diabetic Potential of Quercetagitrin through Dual Inhibition of PTPN6 and PTPN9
Protein tyrosine phosphatases (PTPs) are pivotal contributors to the development of type 2 diabetes (T2DM). Hence, directing interventions towards PTPs emerges as a valuable therapeutic approach for managing type 2 diabetes. In particular, PTPN6 and PTPN9 are targets for anti-diabetic effects. Through high-throughput drug screening, quercetagitrin (QG) was recognized as a dual-target inhibitor of PTPN6 and PTPN9. We observed that QG suppressed the catalytic activity of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM) in vitro and enhanced glucose uptake by mature C2C12 myoblasts. Additionally, QG increased the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and insulin-dependent phosphorylation of Akt in mature C2C12 myoblasts. It further promoted the phosphorylation of Akt in the presence of palmitic acid, suggesting the attenuation of insulin resistance. In summary, our results indicate QG’s role as a potent inhibitor targeting both PTPN6 and PTPN9, showcasing its potential as a promising treatment avenue for T2DM.
Open AccessExploring the Anti-Diabetic Potential of Quercetagitrin through Dual Inhibition of PTPN6 and PTPN9
Protein tyrosine phosphatases (PTPs) are pivotal contributors to the development of type 2 diabetes (T2DM). Hence, directing interventions towards PTPs emerges as a valuable therapeutic approach for managing type 2 diabetes. In particular, PTPN6 and PTPN9 are targets for anti-diabetic effects. Through high-throughput drug screening, quercetagitrin (QG) was recognized as a dual-target inhibitor of PTPN6 and PTPN9. We observed that QG suppressed the catalytic activity of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM) in vitro and enhanced glucose uptake by mature C2C12 myoblasts. Additionally, QG increased the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and insulin-dependent phosphorylation of Akt in mature C2C12 myoblasts. It further promoted the phosphorylation of Akt in the presence of palmitic acid, suggesting the attenuation of insulin resistance. In summary, our results indicate QG’s role as a potent inhibitor targeting both PTPN6 and PTPN9, showcasing its potential as a promising treatment avenue for T2DM.
- 6 January 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 99, 117587
Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity
- 6 January 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 99, 117587
Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity
- Open Access
Identification of Crocetin as a Dual Agonist of GPR40 and GPR120 Responsible for the Antidiabetic Effect of Saffron
Crocin, a glycoside of crocetin, has been known as the principal component responsible for saffron’s antidiabetic, anticancer, and anti-inflammatory effects. Crocetin, originating from the hydrolytic cleavage of crocin in biological systems, was subjected to ligand-based virtual screening in this investigation. Subsequent biochemical analysis unveiled crocetin, not crocin, as a novel dual GPR40 and GPR120 agonist, demonstrating a marked preference for GPR40 and GPR120 over peroxisome proliferator-activated receptors (PPAR)γ. This compound notably enhanced insulin and GLP-1 secretion from pancreatic β-cells and intestinal neuroendocrine cells, respectively, presenting a dual mechanism of action in glucose-lowering effects. Docking simulations showed that crocetin emulates the binding characteristics of natural ligands through hydrogen bonds and hydrophobic interactions, whereas crocin’s hindered fit within the binding pocket is attributed to steric constraints. Collectively, for the first time, this study unveils crocetin as the true active component of saffron, functioning as a GPR40/120 agonist with potential implications in antidiabetic interventions.
Open AccessIdentification of Crocetin as a Dual Agonist of GPR40 and GPR120 Responsible for the Antidiabetic Effect of Saffron
Crocin, a glycoside of crocetin, has been known as the principal component responsible for saffron’s antidiabetic, anticancer, and anti-inflammatory effects. Crocetin, originating from the hydrolytic cleavage of crocin in biological systems, was subjected to ligand-based virtual screening in this investigation. Subsequent biochemical analysis unveiled crocetin, not crocin, as a novel dual GPR40 and GPR120 agonist, demonstrating a marked preference for GPR40 and GPR120 over peroxisome proliferator-activated receptors (PPAR)γ. This compound notably enhanced insulin and GLP-1 secretion from pancreatic β-cells and intestinal neuroendocrine cells, respectively, presenting a dual mechanism of action in glucose-lowering effects. Docking simulations showed that crocetin emulates the binding characteristics of natural ligands through hydrogen bonds and hydrophobic interactions, whereas crocin’s hindered fit within the binding pocket is attributed to steric constraints. Collectively, for the first time, this study unveils crocetin as the true active component of saffron, functioning as a GPR40/120 agonist with potential implications in antidiabetic interventions.
- Open Access
- 30 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (9) , 5020
Ethyl Gallate Dual-Targeting PTPN6 and PPARγ Shows Anti-Diabetic and Anti-Obese Effects
The emergence of the high correlation between type 2 diabetes and obesity with complicated conditions has led to the coinage of the term “diabesity”. AMP-activated protein kinase (AMPK) activators and peroxisome proliferator-activated receptor (PPARγ) antagonists have shown therapeutic activity for diabesity, respectively. Hence, the discovery of compounds that activate AMPK as well as antagonize PPARγ may lead to the discovery of novel therapeutic agents for diabesity. In this study, the knockdown of PTPN6 activated AMPK and suppressed adipogenesis in 3T3-L1 cells. By screening a library of 1033 natural products against PTPN6, we found ethyl gallate to be the most selective inhibitor of PTPN6 (Ki = 3.4 μM). Subsequent assay identified ethyl gallate as the best PPARγ antagonist (IC50 = 5.4 μM) among the hit compounds inhibiting PTPN6. Ethyl gallate upregulated glucose uptake and downregulated adipogenesis in 3T3-L1 cells as anticipated. These results strongly suggest that ethyl gallate, which targets both PTPN6 and PPARγ, is a potent therapeutic candidate to combat diabesity.
- 30 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (9) , 5020
Open AccessEthyl Gallate Dual-Targeting PTPN6 and PPARγ Shows Anti-Diabetic and Anti-Obese Effects
The emergence of the high correlation between type 2 diabetes and obesity with complicated conditions has led to the coinage of the term “diabesity”. AMP-activated protein kinase (AMPK) activators and peroxisome proliferator-activated receptor (PPARγ) antagonists have shown therapeutic activity for diabesity, respectively. Hence, the discovery of compounds that activate AMPK as well as antagonize PPARγ may lead to the discovery of novel therapeutic agents for diabesity. In this study, the knockdown of PTPN6 activated AMPK and suppressed adipogenesis in 3T3-L1 cells. By screening a library of 1033 natural products against PTPN6, we found ethyl gallate to be the most selective inhibitor of PTPN6 (Ki = 3.4 μM). Subsequent assay identified ethyl gallate as the best PPARγ antagonist (IC50 = 5.4 μM) among the hit compounds inhibiting PTPN6. Ethyl gallate upregulated glucose uptake and downregulated adipogenesis in 3T3-L1 cells as anticipated. These results strongly suggest that ethyl gallate, which targets both PTPN6 and PPARγ, is a potent therapeutic candidate to combat diabesity.
- Open Access
- 1 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (7) , 3927
Structure–Activity Relationship of Synthetic Ginkgolic Acid Analogs for Treating Type 2 Diabetes by PTPN9 Inhibition
Ginkgolic acid (C13:0) (GA), isolated from Ginkgo biloba, is a potential therapeutic agent for type 2 diabetes. A series of GA analogs were designed and synthesized for the evaluation of their structure–activity relationship with respect to their antidiabetic effects. Unlike GA, the synthetic analog 1e exhibited improved inhibitory activity against PTPN9 and significantly stimulated glucose uptake via AMPK phosphorylation in differentiated 3T3-L1 adipocytes and C2C12 myotubes; it also induced insulin-dependent AKT activation in C2C12 myotubes in a concentration-dependent manner. Docking simulation results showed that 1e had a better binding affinity through a unique hydrophobic interaction with a PTPN9 hydrophobic groove. Moreover, 1e ameliorated palmitate-induced insulin resistance in C2C12 cells. This study showed that 1e increases glucose uptake and suppresses palmitate-induced insulin resistance in C2C12 myotubes via PTPN9 inhibition; thus, it is a promising therapeutic candidate for treating type 2 diabetes.
- 1 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (7) , 3927
Open AccessStructure–Activity Relationship of Synthetic Ginkgolic Acid Analogs for Treating Type 2 Diabetes by PTPN9 Inhibition
Ginkgolic acid (C13:0) (GA), isolated from Ginkgo biloba, is a potential therapeutic agent for type 2 diabetes. A series of GA analogs were designed and synthesized for the evaluation of their structure–activity relationship with respect to their antidiabetic effects. Unlike GA, the synthetic analog 1e exhibited improved inhibitory activity against PTPN9 and significantly stimulated glucose uptake via AMPK phosphorylation in differentiated 3T3-L1 adipocytes and C2C12 myotubes; it also induced insulin-dependent AKT activation in C2C12 myotubes in a concentration-dependent manner. Docking simulation results showed that 1e had a better binding affinity through a unique hydrophobic interaction with a PTPN9 hydrophobic groove. Moreover, 1e ameliorated palmitate-induced insulin resistance in C2C12 cells. This study showed that 1e increases glucose uptake and suppresses palmitate-induced insulin resistance in C2C12 myotubes via PTPN9 inhibition; thus, it is a promising therapeutic candidate for treating type 2 diabetes.